Long-term clinical outcomes with <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).Sumanta Kumar Pal, Seiya Higashi, Peter P. Lee et al.|Journal of Clinical Oncology|2026Cited by 0
Genomic characterization of upper tract urothelial carcinoma (UTUC) with or without sarcomatoid differentiation.Salvador Jaime-Casas, Abhishek Tripathi, T. Dorff et al.|Journal of Clinical Oncology|2026Cited by 0
Availability of clinical trials investigating prostate cancer (PC) in the United States (US).Benjamin Mercier, Sumanta Kumar Pal, Miguel Zugman et al.|Journal of Clinical Oncology|2026Cited by 0
Abstract 3911: Use of ALK inhibitors in patients with non-lung malignancies bearing <i>ALK</i> alteration prolongs treatment duration.Vitor Góes, Sumanta Kumar Pal, Miguel Zugman et al.|Cancer Research|2026Cited by 0